Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy

W. Magliani, S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi, L. Polonelli

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFv-susceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.

Original languageEnglish
Pages (from-to)1793-1800
Number of pages8
JournalCurrent Medicinal Chemistry
Volume11
Issue number13
Publication statusPublished - Jul 2004

Fingerprint

Glucans
Microorganisms
Peptides
Yeast Killer Factor
Therapeutic Uses
Cells
Cell Wall
Immunoglobulin Fragments
Peptide Fragments
Antibodies
Candida
Alanine
Yeast
Pichia
Epitopes
Therapeutics
Vaccines
Candida albicans
Anti-Bacterial Agents
Scanning

Keywords

  • Antiidiotypic antibiotics
  • Antiidiotypic therapy
  • Antimicrobial therapy
  • Killer mimotopes
  • Synthetic peptides
  • Yeast killer toxin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Organic Chemistry
  • Pharmacology

Cite this

Magliani, W., Conti, S., Salati, A., Arseni, S., Ravanetti, L., Frazzi, R., & Polonelli, L. (2004). Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy. Current Medicinal Chemistry, 11(13), 1793-1800.

Engineered killer mimotopes : New synthetic peptides for antimicrobial therapy. / Magliani, W.; Conti, S.; Salati, A.; Arseni, S.; Ravanetti, L.; Frazzi, R.; Polonelli, L.

In: Current Medicinal Chemistry, Vol. 11, No. 13, 07.2004, p. 1793-1800.

Research output: Contribution to journalArticle

Magliani, W, Conti, S, Salati, A, Arseni, S, Ravanetti, L, Frazzi, R & Polonelli, L 2004, 'Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy', Current Medicinal Chemistry, vol. 11, no. 13, pp. 1793-1800.
Magliani W, Conti S, Salati A, Arseni S, Ravanetti L, Frazzi R et al. Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy. Current Medicinal Chemistry. 2004 Jul;11(13):1793-1800.
Magliani, W. ; Conti, S. ; Salati, A. ; Arseni, S. ; Ravanetti, L. ; Frazzi, R. ; Polonelli, L. / Engineered killer mimotopes : New synthetic peptides for antimicrobial therapy. In: Current Medicinal Chemistry. 2004 ; Vol. 11, No. 13. pp. 1793-1800.
@article{f1eb645d07014261a4985518614fc706,
title = "Engineered killer mimotopes: New synthetic peptides for antimicrobial therapy",
abstract = "This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFv-susceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.",
keywords = "Antiidiotypic antibiotics, Antiidiotypic therapy, Antimicrobial therapy, Killer mimotopes, Synthetic peptides, Yeast killer toxin",
author = "W. Magliani and S. Conti and A. Salati and S. Arseni and L. Ravanetti and R. Frazzi and L. Polonelli",
year = "2004",
month = "7",
language = "English",
volume = "11",
pages = "1793--1800",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Engineered killer mimotopes

T2 - New synthetic peptides for antimicrobial therapy

AU - Magliani, W.

AU - Conti, S.

AU - Salati, A.

AU - Arseni, S.

AU - Ravanetti, L.

AU - Frazzi, R.

AU - Polonelli, L.

PY - 2004/7

Y1 - 2004/7

N2 - This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFv-susceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.

AB - This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFv-susceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.

KW - Antiidiotypic antibiotics

KW - Antiidiotypic therapy

KW - Antimicrobial therapy

KW - Killer mimotopes

KW - Synthetic peptides

KW - Yeast killer toxin

UR - http://www.scopus.com/inward/record.url?scp=3042626481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042626481&partnerID=8YFLogxK

M3 - Article

C2 - 15279582

AN - SCOPUS:3042626481

VL - 11

SP - 1793

EP - 1800

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 13

ER -